Notably, since plaque formation on IFN-α/γ pretreated Vero cells of wild-type HSV-1 dropped up to 100-fold, we performed inoculations with 100-fold higher virus doses for the IFN-α/γ combination treatment (i.e., a multiplicity of infection [MOI] of 0.1 for the IFN-α/γ pretreated Vero cells and a MOI of 0.001 for untreated or IFN-α pretreated Vero cells). The gene discussed is IFNA2; the disease is infection.